Last reviewed · How we verify

Congenital hypothyroidism - replacement therapy — Treatment Landscape & Competitive Intelligence

Congenital hypothyroidism - replacement therapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Congenital hypothyroidism - replacement therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Levoxyl Levothyroxine Sodium Pfizer Inc. Thyroid hormone replacement Thyroid receptor proteins attached to DNA

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Congenital hypothyroidism - replacement therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital hypothyroidism - replacement therapy:

Cite this brief

Drug Landscape (2026). Congenital hypothyroidism - replacement therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-hypothyroidism-replacement-therapy. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing